Global Cystic Fibrosis Market 2015-2019: Key Vendors are Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis and Vertex Pharmaceuticals
DUBLIN, Jan. 29, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/xhxxpz/global_cystic) has announced the addition of the "Global Cystic Fibrosis Market 2015-2019" report to their offering.
Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country.
Cystic fibrosis is a chronic disease. The production of a high-salt containing sweat and secretion of abnormal viscous mucus are the major symptoms of cystic fibrosis.
The analysts forecast the Global Cystic Fibrosis market to grow at a CAGR of 32.50 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global Cystic Fibrosis market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis which includes:
- Small Molecules
- Biologics
Further, the market is segmented on based on route of administration and dosage form. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Cystic Fibrosis market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
The report, the Global Cystic Fibrosis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA region; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
CFTR modulator drugs are increasingly becoming the preferred choice of treatment for cystic fibrosis as these drugs target the molecular cause of cystic fibrosis. Since these drugs target the cause of the disease, they are gaining popularity among patients and the medical community as a preferred choice for the treatment of cystic fibrosis.
According to the report, the primary driver of this market is the high degree of unmet needs for appropriate drugs in the market. There is no cure for cystic fibrosis and the mortality rate is high. Therefore, drugs that can achieve remission of the disease in patients are expected to drive the growth of the market.
Further, the report states that the high cost of therapy is a major factor that restricts the growth of the market. Patients tend to withdraw from treatment, deterred by the high costs. Medication and hospitalization costs account for the largest share of the expenditure of a cystic fibrosis patient, followed by medical services, costs resulting from other complications, and diagnostic charges. This results in high overall expenditure.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
06. Introduction
07. Disease Overview
08. Market Landscape
09. Market Segmentation by Molecule Type
10. Market Segmentation by Route of Administration
11. Market Segmentation by Dosage Form
12. Geographical Segmentation
13. Key Leading Countries
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
22. Key Vendor Analysis
23. Other Reports in this Series
Companies Mentioned:
- Abbott
- Actavis
- Anthera Pharmaceuticals
- Arcturus Therapeutics
- Boehringer Ingelheim
- Chiesi Farmaceutici
- F. Hoffmann-La Roche
- Genzyme
- Gilead Sciences
- Insmed
- Johnson & Johnson
- Merck Sharp & Dohme
- Neovii Biotech
- Novartis
- Novo Nordisk
- PTC Therapeutics
- PharmaSwiss
- Pharmaxis
- Proteostasis Therapeutics
- United Medical
- Venus Remedies
- Vertex Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/xhxxpz/global_cystic
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article